From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.54
First Reported 2003
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 7
Total Number 7
Disease Relevance 6.79
Pain Relevance 0.25

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleoplasm (BRCA2) chromosome organization (BRCA2) nucleolus (BRCA2)
nucleus (BRCA2) cell cycle (BRCA2) DNA binding (BRCA2)
Anatomy Link Frequency
filament 1
BRCA2 (Homo sapiens)
Pain Link Frequency Relevance Heat
endometriosis 1 94.48 High High
cva 22 91.96 High High
transdermal 1 90.90 High High
COX-2 inhibitor 3 54.88 Quite High
chemokine 99 50.00 Quite Low
Chronic pancreatitis 4 49.52 Quite Low
alcohol 2 42.92 Quite Low
imagery 54 40.40 Quite Low
Inflammation 12 5.00 Very Low Very Low Very Low
antagonist 10 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Cancer 549 100.00 Very High Very High Very High
Malignant Neoplastic Disease 36 99.92 Very High Very High Very High
Hyperplasia 22 99.64 Very High Very High Very High
Breast Cancer 657 99.62 Very High Very High Very High
Disease 164 98.88 Very High Very High Very High
Skin Cancer 1 98.72 Very High Very High Very High
Noninfiltrating Intraductal Carcinoma 64 98.52 Very High Very High Very High
Ductal Carcinoma 2 98.24 Very High Very High Very High
Lobular Carcinoma 2 97.58 Very High Very High Very High
Reprotox - General 1 40 97.20 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Equally, several studies have indicated the importance of considering specific lesions in relation to therapeutic response, for example, Aurora kinase overexpression and taxane resistance, BRCA2 loss and response to platinum-based therapy [67], topoisomerase II alpha amplification and epirubicin response [68].
Negative_regulation (loss) of BRCA2
1) Confidence 0.54 Published 2008 Journal Breast Cancer Res Section Body Doc Link PMC2397525 Disease Relevance 0.29 Pain Relevance 0.03
Only a relatively small proportion of breast cancers are caused by the loss of BRCA1 or BRCA2 function; most arise as a result of somatic mutation or changes in expression of a number of other genes.
Negative_regulation (loss) of BRCA2 associated with breast cancer
2) Confidence 0.54 Published 2008 Journal Breast Cancer Res Section Body Doc Link PMC2397525 Disease Relevance 0.60 Pain Relevance 0
The exclusion criteria for randomisation were:

• For the placebo controlled components: oral or transdermal HRT use in the last six months, ever use of HRT implant in women with a uterus, HRT implant inserted in last eight months in women with a hysterectomy. • History of endometriosis (hysterectomised or non-hysterectomised woman) or endometrial hyperplasia in a woman with a uterus. • History of invasive breast cancer, lobular carcinoma in-situ (LCIS), ductal carcinoma in-situ (DCIS), Paget's disease of the nipple or atypical hyperplasia of the breast. • Known BRCA1 or BRCA2 mutation carrier. • History of melanoma. • Invasive cancer at any other site apart from basal and squamous cell skin cancer within the last 10 years. • History of meningioma. • Myocardial infarction, cerebrovascular accident, sub-arachnoid haemorrhage or transient ischaemic attack within the last six months. • History of currently active liver disease or chronic liver disease but excluding Hepatitis A unless currently active. • Evidence of severe current renal impairment. • History of gall bladder disease in a woman who had not had a cholecystectomy or of gallstones following a cholecystectomy. • History of deep vein thrombosis, pulmonary embolism or retinal vein occlusion. • Positive thrombophilia screen (Factor V Leiden or prothrombin mutations, Protein C, Protein S or anti-thrombin III deficiencies, APC resistance, dysfibrinogenaemia or antiphospholipid antibodies). • Otosclerosis. • Porphyria. • History of hepatitis B, hepatitis C or HIV (not an exclusion in New Zealand). • Currently pregnant. • Currently taking or has taken contraceptive drugs in the last 12 months. • Current triglyceride level (fasting) > 5.5 mmol/l. • Active participant in any other intervention trial likely to affect trial outcomes. • Taking tamoxifen, toremifene, raloxifene or any other selective oestrogen receptor modulator (SERM). • Other conditions/circumstances where the general practitioner judged that it would not be possible to obtain fully informed consent and/or successfully complete trial procedures.

Negative_regulation (Known) of BRCA2 associated with porphyria, endometriosis (extended), cv general 4 under development, skin cancer, hyperplasia, liver disease, endometriosis, conductive hearing loss, hepatitis, brain tumor, lobular carcinoma, thrombophilia, gallbladder disease, gallstones, hepatitis a virus infection, disease, retinal vein occlusion, thrombosis, pulmonary embolism, ductal carcinoma, transdermal, cancer, basal and squamous cell skin cancer, acquired immune deficiency syndrome or hiv infection, noninfiltrating intraductal carcinoma, cva, reprotox - general 1 and myocardial infarction
3) Confidence 0.41 Published 2007 Journal BMC Womens Health Section Body Doc Link PMC1828722 Disease Relevance 2.56 Pain Relevance 0.22
Cells deficient in BRCA1 and BRCA2 are extremely sensitive to DNA-damaging agents and are defective in repairing DNA double-strand breaks by homologous recombination, being impaired in the recruitment and filament formation of the recombination protein RAD51 [9,10].
Negative_regulation (defective) of BRCA2 in filament
4) Confidence 0.39 Published 2008 Journal Breast Cancer Res Section Body Doc Link PMC2397525 Disease Relevance 0.45 Pain Relevance 0
Loss of other tumor suppressor genes like p53, BRCA2 and DPC4 (Smad4) occurs later in neoplasia development.
Negative_regulation (Loss) of BRCA2 associated with cancer
5) Confidence 0.34 Published 2003 Journal Mol Cancer Section Body Doc Link PMC151686 Disease Relevance 1.31 Pain Relevance 0
However, alterations in DNA repair caused by defects in BRCA1 and BRCA2 may enhance the sensitivity of BRCA-positive tumors to platinum agents such as cisplatin and carboplatin, which cross-link DNA and interfere with replication [35].
Negative_regulation (defects) of BRCA2 associated with cancer
6) Confidence 0.31 Published 2010 Journal Current Genomics Section Body Doc Link PMC2878980 Disease Relevance 0.65 Pain Relevance 0
Loss of heterozigosity and mutations BRCA1 and BRCA2 leading to inactivation of other genes, has been described in familial ovarian cancers [55].
Negative_regulation (Loss) of BRCA2 associated with ovarian cancer
7) Confidence 0.30 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2798669 Disease Relevance 0.94 Pain Relevance 0

General Comments

This test has worked.

Personal tools